You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Fortical Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Fortical patents expire, and when can generic versions of Fortical launch?

Fortical is a drug marketed by Upsher Smith Labs and is included in one NDA.

The generic ingredient in FORTICAL is calcitonin salmon recombinant. There are fourteen drug master file entries for this compound. Additional details are available on the calcitonin salmon recombinant profile page.

Summary for Fortical
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 16
Clinical Trials: 1
Patent Applications: 379
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in Fortical?Fortical excipients list
DailyMed Link:Fortical at DailyMed
Drug patent expirations by year for Fortical
Recent Clinical Trials for Fortical

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Yale UniversityN/A
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)N/A

See all Fortical clinical trials

Paragraph IV (Patent) Challenges for FORTICAL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FORTICAL Nasal Spray calcitonin salmon recombinant 200 IU/spray 021406 1 2006-03-29

US Patents and Regulatory Information for Fortical

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher Smith Labs FORTICAL calcitonin salmon recombinant SPRAY, METERED;NASAL 021406-001 Aug 12, 2005 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Fortical

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upsher Smith Labs FORTICAL calcitonin salmon recombinant SPRAY, METERED;NASAL 021406-001 Aug 12, 2005 ⤷  Try a Trial ⤷  Try a Trial
Upsher Smith Labs FORTICAL calcitonin salmon recombinant SPRAY, METERED;NASAL 021406-001 Aug 12, 2005 ⤷  Try a Trial ⤷  Try a Trial
Upsher Smith Labs FORTICAL calcitonin salmon recombinant SPRAY, METERED;NASAL 021406-001 Aug 12, 2005 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for Fortical

See the table below for patents covering Fortical around the world.

Country Patent Number Title Estimated Expiration
China 1183965 ⤷  Try a Trial
China 1422160 ⤷  Try a Trial
European Patent Office 1251867 ⤷  Try a Trial
Australia 783952 ⤷  Try a Trial
Canada 2399505 FORMULATIONS DE CALCITONINE POUR ADMINISTRATION PAR VOIE NASALE (NASAL CALCITONIN FORMULATIONS) ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 0156594 ⤷  Try a Trial
Australia 3660401 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.